Astria Therapeutics (NASDAQ:ATXS) PT Lowered to $25.00

Astria Therapeutics (NASDAQ:ATXS) had its target price cut by analysts at Oppenheimer from $30.00 to $25.00 in a report issued on Wednesday, Benzinga reports. The brokerage currently has an “outperform” rating on the biotechnology company’s stock. Oppenheimer’s price target points to a potential upside of 453.10% from the stock’s previous close.

ATXS has been the topic of a number of other reports. HC Wainwright cut their price objective on shares of Astria Therapeutics from $20.00 to $18.00 and set a “buy” rating on the stock in a research note on Thursday, October 12th. Wedbush cut their price objective on shares of Astria Therapeutics from $25.00 to $18.00 and set an “outperform” rating on the stock in a research note on Friday, October 13th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $19.75.

Astria Therapeutics Trading Up 0.7 %

ATXS stock opened at $4.52 on Wednesday. The company has a market capitalization of $126.74 million, a P/E ratio of -2.05 and a beta of 0.90. The firm has a 50 day simple moving average of $6.25 and a 200-day simple moving average of $8.70. Astria Therapeutics has a twelve month low of $4.27 and a twelve month high of $16.28.

Insider Activity

In other news, Director Perceptive Advisors Llc purchased 1,074,608 shares of Astria Therapeutics stock in a transaction dated Monday, October 16th. The stock was acquired at an average cost of $6.51 per share, for a total transaction of $6,995,698.08. Following the acquisition, the director now directly owns 1,652,371 shares in the company, valued at $10,756,935.21. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 3.40% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Astria Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in ATXS. UBS Group AG lifted its holdings in shares of Astria Therapeutics by 66,700.0% during the first quarter. UBS Group AG now owns 2,672 shares of the biotechnology company’s stock worth $36,000 after buying an additional 2,668 shares during the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of Astria Therapeutics by 416.5% during the third quarter. Tower Research Capital LLC TRC now owns 3,357 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 2,707 shares during the last quarter. California State Teachers Retirement System bought a new stake in shares of Astria Therapeutics during the second quarter worth $71,000. Citigroup Inc. acquired a new position in shares of Astria Therapeutics during the first quarter valued at $117,000. Finally, Wells Fargo & Company MN lifted its stake in Astria Therapeutics by 6,403.7% in the second quarter. Wells Fargo & Company MN now owns 10,536 shares of the biotechnology company’s stock valued at $88,000 after buying an additional 10,374 shares during the period. 87.85% of the stock is currently owned by institutional investors and hedge funds.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in clinical development stage for the treatment of hereditary angioedema.